Coaprovel 150\12.5mg 14 Tablets

Medication Name: Coaprovel 150/12.5mg 14 Tablets

Active Ingredients (per tablet):

• Irbesartan 150 mg

• Hydrochlorothiazide 12.5 mg

Pharmacological Class:

• Irbesartan: Angiotensin II receptor blocker (ARB)

• Hydrochlorothiazide: Thiazide diuretic

Dosage Form:
Tablets — 14 per pack

Indications:

• Treatment of essential hypertension (high blood pressure).

• Particularly indicated in patients whose blood pressure is not adequately controlled by monotherapy with irbesartan or hydrochlorothiazide.

Mechanism of Action:

• Irbesartan: Selectively blocks angiotensin II receptors (AT1 subtype), preventing vasoconstriction and aldosterone release, which reduces blood pressure and vascular resistance.

• Hydrochlorothiazide: Inhibits sodium and chloride reabsorption in the distal tubules of the kidney, promoting diuresis and reducing blood volume.

• The combination provides additive antihypertensive effects through complementary mechanisms.

Dosage:

• Usual dose: One tablet once daily, with or without food.

• Dose may be adjusted depending on blood pressure response; higher strengths (e.g., 300/12.5mg or 300/25mg) are available for patients needing greater control.

Precautions:

• Monitor renal function, serum potassium, sodium, and blood pressure regularly.

• Use with caution in renal or hepatic impairment, diabetes, or patients on diuretics.

• Contraindicated in pregnancy, severe renal failure, anuria, and hypersensitivity to sulfonamide-derived drugs.

• Avoid concomitant use with potassium supplements or potassium-sparing diuretics unless advised by a physician.

Common Side Effects:

• Dizziness, especially at treatment initiation

• Fatigue

• Headache

• Nausea

• Muscle cramps or weakness

• Hypotension

• Changes in electrolytes (low potassium or sodium levels)

Note:
Coaprovel 150/12.5mg offers effective dual-action blood pressure control by combining angiotensin II receptor blockade with gentle diuretic action, reducing cardiovascular risk in hypertensive patients who require combination therapy.